Global CD19-targeted CAR-T Cell Therapy Market Analysis and Forecast 2025-2031

Summary

According to APO Research, The global CD19-targeted CAR-T Cell Therapy market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CD19-targeted CAR-T Cell Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for CD19-targeted CAR-T Cell Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for CD19-targeted CAR-T Cell Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for CD19-targeted CAR-T Cell Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of CD19-targeted CAR-T Cell Therapy include Bristol-Myers Squibb (Breyanzi), Gilead (Yescarta&Tecartus), Novartis (Kymriah), FOSUNKite (Yescarta), Juventas and Shanghai Yaoming Juno (Carteyva), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CD19-targeted CAR-T Cell Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of CD19-targeted CAR-T Cell Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for CD19-targeted CAR-T Cell Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CD19-targeted CAR-T Cell Therapy revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global CD19-targeted CAR-T Cell Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for CD19-targeted CAR-T Cell Therapy revenue, projected growth trends, production technology, application and end-user industry.

CD19-targeted CAR-T Cell Therapy Segment by Company

Bristol-Myers Squibb (Breyanzi)
Gilead (Yescarta&Tecartus)
Novartis (Kymriah)
FOSUNKite (Yescarta)
Juventas
Shanghai Yaoming Juno (Carteyva)

CD19-targeted CAR-T Cell Therapy Segment by Type

Yescarta
Tecartus
Kymriah
Others

CD19-targeted CAR-T Cell Therapy Segment by Application

Lymphoma
Lymphocytic Leukemia

CD19-targeted CAR-T Cell Therapy Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD19-targeted CAR-T Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CD19-targeted CAR-T Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD19-targeted CAR-T Cell Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of CD19-targeted CAR-T Cell Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of CD19-targeted CAR-T Cell Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CD19-targeted CAR-T Cell Therapy revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 CD19-targeted CAR-T Cell Therapy Market by Type
1.2.1 Global CD19-targeted CAR-T Cell Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Yescarta
1.2.3 Tecartus
1.2.4 Kymriah
1.2.5 Others
1.3 CD19-targeted CAR-T Cell Therapy Market by Application
1.3.1 Global CD19-targeted CAR-T Cell Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Lymphoma
1.3.3 Lymphocytic Leukemia
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 CD19-targeted CAR-T Cell Therapy Market Dynamics
2.1 CD19-targeted CAR-T Cell Therapy Industry Trends
2.2 CD19-targeted CAR-T Cell Therapy Industry Drivers
2.3 CD19-targeted CAR-T Cell Therapy Industry Opportunities and Challenges
2.4 CD19-targeted CAR-T Cell Therapy Industry Restraints
3 Global Growth Perspective
3.1 Global CD19-targeted CAR-T Cell Therapy Market Perspective (2020-2031)
3.2 Global CD19-targeted CAR-T Cell Therapy Growth Trends by Region
3.2.1 Global CD19-targeted CAR-T Cell Therapy Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global CD19-targeted CAR-T Cell Therapy Market Size by Region (2020-2025)
3.2.3 Global CD19-targeted CAR-T Cell Therapy Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global CD19-targeted CAR-T Cell Therapy Revenue by Players
4.1.1 Global CD19-targeted CAR-T Cell Therapy Revenue by Players (2020-2025)
4.1.2 Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Players (2020-2025)
4.1.3 Global CD19-targeted CAR-T Cell Therapy Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global CD19-targeted CAR-T Cell Therapy Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global CD19-targeted CAR-T Cell Therapy Key Players Headquarters & Area Served
4.4 Global CD19-targeted CAR-T Cell Therapy Players, Product Type & Application
4.5 Global CD19-targeted CAR-T Cell Therapy Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global CD19-targeted CAR-T Cell Therapy Market CR5 and HHI
4.6.3 2024 CD19-targeted CAR-T Cell Therapy Tier 1, Tier 2, and Tier 3
5 CD19-targeted CAR-T Cell Therapy Market Size by Type
5.1 Global CD19-targeted CAR-T Cell Therapy Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global CD19-targeted CAR-T Cell Therapy Revenue by Type (2020-2031)
5.3 Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Type (2020-2031)
6 CD19-targeted CAR-T Cell Therapy Market Size by Application
6.1 Global CD19-targeted CAR-T Cell Therapy Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global CD19-targeted CAR-T Cell Therapy Revenue by Application (2020-2031)
6.3 Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Bristol-Myers Squibb (Breyanzi)
7.1.1 Bristol-Myers Squibb (Breyanzi) Comapny Information
7.1.2 Bristol-Myers Squibb (Breyanzi) Business Overview
7.1.3 Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
7.1.4 Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Product Portfolio
7.1.5 Bristol-Myers Squibb (Breyanzi) Recent Developments
7.2 Gilead (Yescarta&Tecartus)
7.2.1 Gilead (Yescarta&Tecartus) Comapny Information
7.2.2 Gilead (Yescarta&Tecartus) Business Overview
7.2.3 Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
7.2.4 Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Product Portfolio
7.2.5 Gilead (Yescarta&Tecartus) Recent Developments
7.3 Novartis (Kymriah)
7.3.1 Novartis (Kymriah) Comapny Information
7.3.2 Novartis (Kymriah) Business Overview
7.3.3 Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
7.3.4 Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Product Portfolio
7.3.5 Novartis (Kymriah) Recent Developments
7.4 FOSUNKite (Yescarta)
7.4.1 FOSUNKite (Yescarta) Comapny Information
7.4.2 FOSUNKite (Yescarta) Business Overview
7.4.3 FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
7.4.4 FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Product Portfolio
7.4.5 FOSUNKite (Yescarta) Recent Developments
7.5 Juventas
7.5.1 Juventas Comapny Information
7.5.2 Juventas Business Overview
7.5.3 Juventas CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
7.5.4 Juventas CD19-targeted CAR-T Cell Therapy Product Portfolio
7.5.5 Juventas Recent Developments
7.6 Shanghai Yaoming Juno (Carteyva)
7.6.1 Shanghai Yaoming Juno (Carteyva) Comapny Information
7.6.2 Shanghai Yaoming Juno (Carteyva) Business Overview
7.6.3 Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2020-2025)
7.6.4 Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Product Portfolio
7.6.5 Shanghai Yaoming Juno (Carteyva) Recent Developments
8 North America
8.1 North America CD19-targeted CAR-T Cell Therapy Revenue (2020-2031)
8.2 North America CD19-targeted CAR-T Cell Therapy Revenue by Type (2020-2031)
8.2.1 North America CD19-targeted CAR-T Cell Therapy Revenue by Type (2020-2025)
8.2.2 North America CD19-targeted CAR-T Cell Therapy Revenue by Type (2026-2031)
8.3 North America CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2020-2031)
8.4 North America CD19-targeted CAR-T Cell Therapy Revenue by Application (2020-2031)
8.4.1 North America CD19-targeted CAR-T Cell Therapy Revenue by Application (2020-2025)
8.4.2 North America CD19-targeted CAR-T Cell Therapy Revenue by Application (2026-2031)
8.5 North America CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2020-2031)
8.6 North America CD19-targeted CAR-T Cell Therapy Revenue by Country
8.6.1 North America CD19-targeted CAR-T Cell Therapy Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America CD19-targeted CAR-T Cell Therapy Revenue by Country (2020-2025)
8.6.3 North America CD19-targeted CAR-T Cell Therapy Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe CD19-targeted CAR-T Cell Therapy Revenue (2020-2031)
9.2 Europe CD19-targeted CAR-T Cell Therapy Revenue by Type (2020-2031)
9.2.1 Europe CD19-targeted CAR-T Cell Therapy Revenue by Type (2020-2025)
9.2.2 Europe CD19-targeted CAR-T Cell Therapy Revenue by Type (2026-2031)
9.3 Europe CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2020-2031)
9.4 Europe CD19-targeted CAR-T Cell Therapy Revenue by Application (2020-2031)
9.4.1 Europe CD19-targeted CAR-T Cell Therapy Revenue by Application (2020-2025)
9.4.2 Europe CD19-targeted CAR-T Cell Therapy Revenue by Application (2026-2031)
9.5 Europe CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2020-2031)
9.6 Europe CD19-targeted CAR-T Cell Therapy Revenue by Country
9.6.1 Europe CD19-targeted CAR-T Cell Therapy Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe CD19-targeted CAR-T Cell Therapy Revenue by Country (2020-2025)
9.6.3 Europe CD19-targeted CAR-T Cell Therapy Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China CD19-targeted CAR-T Cell Therapy Revenue (2020-2031)
10.2 China CD19-targeted CAR-T Cell Therapy Revenue by Type (2020-2031)
10.2.1 China CD19-targeted CAR-T Cell Therapy Revenue by Type (2020-2025)
10.2.2 China CD19-targeted CAR-T Cell Therapy Revenue by Type (2026-2031)
10.3 China CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2020-2031)
10.4 China CD19-targeted CAR-T Cell Therapy Revenue by Application (2020-2031)
10.4.1 China CD19-targeted CAR-T Cell Therapy Revenue by Application (2020-2025)
10.4.2 China CD19-targeted CAR-T Cell Therapy Revenue by Application (2026-2031)
10.5 China CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia CD19-targeted CAR-T Cell Therapy Revenue (2020-2031)
11.2 Asia CD19-targeted CAR-T Cell Therapy Revenue by Type (2020-2031)
11.2.1 Asia CD19-targeted CAR-T Cell Therapy Revenue by Type (2020-2025)
11.2.2 Asia CD19-targeted CAR-T Cell Therapy Revenue by Type (2026-2031)
11.3 Asia CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2020-2031)
11.4 Asia CD19-targeted CAR-T Cell Therapy Revenue by Application (2020-2031)
11.4.1 Asia CD19-targeted CAR-T Cell Therapy Revenue by Application (2020-2025)
11.4.2 Asia CD19-targeted CAR-T Cell Therapy Revenue by Application (2026-2031)
11.5 Asia CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2020-2031)
11.6 Asia CD19-targeted CAR-T Cell Therapy Revenue by Country
11.6.1 Asia CD19-targeted CAR-T Cell Therapy Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia CD19-targeted CAR-T Cell Therapy Revenue by Country (2020-2025)
11.6.3 Asia CD19-targeted CAR-T Cell Therapy Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA CD19-targeted CAR-T Cell Therapy Revenue (2020-2031)
12.2 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Type (2020-2031)
12.2.1 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Type (2020-2025)
12.2.2 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Type (2026-2031)
12.3 SAMEA CD19-targeted CAR-T Cell Therapy Revenue Share by Type (2020-2031)
12.4 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Application (2020-2031)
12.4.1 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Application (2020-2025)
12.4.2 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Application (2026-2031)
12.5 SAMEA CD19-targeted CAR-T Cell Therapy Revenue Share by Application (2020-2031)
12.6 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Country
12.6.1 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Country (2020-2025)
12.6.3 SAMEA CD19-targeted CAR-T Cell Therapy Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings